Literature DB >> 11564653

Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.

L Zhao1, P Bath, S Heptinstall.   

Abstract

1. Antiplatelet drugs have been demonstrated to reduce the incidence of recurrent events in patients with symptomatic vascular disease. However, there is no experimental data indicating the effects of these agents when given together on platelets and leukocytes. We investigated the ability of aspirin (an inhibitor of cyclo-oxygenase), dipyridamole (an inhibitor of phospodiesterases and adenosine uptake) and AR-C69931 (a direct acting P(2T) antagonist with effects similar to those of clopidogrel which can be used in vitro) when used alone or in combination to inhibit platelet and leukocyte function. 2. Measurements of platelet and leukocyte function were performed in blood taken from normal volunteers, and the inhibitory effects of aspirin (100 micromol l(-1)), dipyridamole (10 micromol l(-1)) and AR-C66931 (100 nmol l(-1)) were determined. Platelet aggregation was induced by stirring blood with and without adenosine diphosphate (ADP) or platelet activating factor (PAF) and measured by platelet counting. Platelet P-selectin expression, platelet-leukocyte conjugate formation, and leukocyte activation were determined by flow cytometry. 3. Dipyridamole, AR-C69931, dipyridamole and AR-C69931, dipyridamole and aspirin, AR-C69931 and aspirin, and all three agents together inhibited platelet aggregation induced by stirring, ADP and PAF (P<0.01). However, it was only the combination of all three agents inhibited P-selectin expression (P<0.01). Similarly, it was the combination of all three antiplatelet agents that most consistently inhibited platelet-monocyte and platelet-neutrophil conjugate formation and monocyte and neutrophil activation. 4. Since both platelets and leukocytes are thought to contribute to arterial thrombosis and atherosclerosis, it is possible that combinations of different antiplatelet agents with different mechanisms of action may afford better protection than individual or pairs of agents used on their own.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564653      PMCID: PMC1572950          DOI: 10.1038/sj.bjp.0704248

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty.

Authors:  C V Serrano; J A Ramires; M Venturinelli; S Arie; E D'Amico; J L Zweier; F Pileggi; P L da Luz
Journal:  J Am Coll Cardiol       Date:  1997-05       Impact factor: 24.094

Review 2.  Stratton lecture 1989. Thrombosis and inflammation as multicellular processes: pathophysiologic significance of transcellular metabolism.

Authors:  A J Marcus
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

3.  Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate formation in whole blood.

Authors:  H M Sanderson; S C Fox; R A Robbins; W Lösche; P Spangenberg; S Heptinstall
Journal:  Platelets       Date:  1998       Impact factor: 3.862

4.  Whole blood platelet function in acute ischemic stroke. Importance of dense body secretion and effects of antithrombotic agents.

Authors:  R Joseph; G D'Andrea; S B Oster; K M Welch
Journal:  Stroke       Date:  1989-01       Impact factor: 7.914

5.  Combination therapy with clopidogrel and aspirin after coronary stenting.

Authors:  D M Kolansky; B D Klugherz; S C Curran; H C Herrmann; K Magness; R L Wilensky; J W Hirshfeld
Journal:  Catheter Cardiovasc Interv       Date:  2000-07       Impact factor: 2.692

6.  A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.

Authors:  R F Storey; J A May; R G Wilcox; S Heptinstall
Journal:  Thromb Haemost       Date:  1999-10       Impact factor: 5.249

7.  A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents.

Authors:  C Müller; H J Büttner; J Petersen; H Roskamm
Journal:  Circulation       Date:  2000-02-15       Impact factor: 29.690

8.  On the mechanism of plasmin-induced platelet aggregation. Implications of the dual role of granule ADP.

Authors:  A Ishii-Watabe; E Uchida; H Mizuguchi; T Hayakawa
Journal:  Biochem Pharmacol       Date:  2000-06-01       Impact factor: 5.858

9.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

Review 10.  Platelet-neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation.

Authors:  G Bazzoni; E Dejana; A Del Maschio
Journal:  Haematologica       Date:  1991 Nov-Dec       Impact factor: 9.941

View more
  12 in total

Review 1.  Central role of the P2Y12 receptor in platelet activation.

Authors:  Robert T Dorsam; Satya P Kunapuli
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

2.  Extensive deendothelialization and thrombogenicity in routinely prepared vein grafts for coronary bypass operations: facts and remedy.

Authors:  Dominik R Weiss; Gerd Juchem; Bernhard M Kemkes; Brigitte Gansera; Stephan Nees
Journal:  Int J Clin Exp Med       Date:  2009-05-28

3.  Improving the Quality of EDTA-treated Blood Specimens from Mice.

Authors:  Catherine J Layssol-Lamour; Fanny A Granat; Ambrine M Sahal; Jean-Pierre D Braun; Catherine Trumel; Nathalie H Bourgès-Abella
Journal:  J Am Assoc Lab Anim Sci       Date:  2022-01-12       Impact factor: 1.706

4.  BF066, a novel dual target antiplatelet agent without significant bleeding.

Authors:  ChangE Pan; Xunbin Wei; Jianqin Ye; Guangda Liu; Si Zhang; Yan Zhang; Hongguang Du; Zhongren Ding
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

5.  Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.

Authors:  Philip M W Bath; Katie Robson; Lisa J Woodhouse; Nikola Sprigg; Robert Dineen; Stuart Pocock
Journal:  Int J Stroke       Date:  2014-12-30       Impact factor: 5.266

6.  Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388).

Authors:  Kailash Krishnan; Maia Beridze; Hanne Christensen; Rob Dineen; Lelia Duley; Stan Heptinstall; Marilyn James; Hugh S Markus; Stuart Pocock; Annemarei Ranta; Thompson Robinson; Nikola Nikola; Graham Venables; Philip Bath
Journal:  Int J Stroke       Date:  2015-06-16       Impact factor: 5.266

7.  Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.

Authors:  Philip M Bath; Lisa J Woodhouse; Jason P Appleton; Maia Beridze; Hanne Christensen; Robert A Dineen; Lelia Duley; Timothy J England; Katie Flaherty; Diane Havard; Stan Heptinstall; Marilyn James; Kailash Krishnan; Hugh S Markus; Alan A Montgomery; Stuart J Pocock; Marc Randall; Annemarei Ranta; Thompson G Robinson; Polly Scutt; Graham S Venables; Nikola Sprigg
Journal:  Lancet       Date:  2017-12-20       Impact factor: 79.321

8.  Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF).

Authors:  Francesco Vieceli Dalla Sega; Francesca Fortini; Giorgio Aquila; Rita Pavasini; Simone Biscaglia; Davide Bernucci; Annamaria Del Franco; Elisabetta Tonet; Paola Rizzo; Roberto Ferrari; Gianluca Campo
Journal:  Front Physiol       Date:  2018-04-06       Impact factor: 4.566

9.  The Dipyridamole Added to Dual Antiplatelet Therapy in Cerebral Infarction After First Acute Myocardial Infarction: A Nationwide, Case-Control Study.

Authors:  Mei-Tzu Wang; Cheng Ken Tsai; Shu-Hung Kuo; Wei-Chun Huang; Kun-Chang Lin; Wang-Ting Hung; Chin-Chang Cheng; Pei-Ling Tang; Cheng Chung Hung; Jin-Shiou Yang; Hsin-Li Liang; Guang-Yuan Mar; Chun-Peng Liu
Journal:  Front Neurol       Date:  2018-11-27       Impact factor: 4.003

10.  A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.

Authors:  Nikola Sprigg; Laura J Gray; Tim England; Mark R Willmot; Lian Zhao; Gillian M Sare; Philip M W Bath
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.